The Mindich Child Health and Development Institute (MCHDI) at the Icahn School of Medicine is a translational research enterprise dedicated to advancing therapies to treat pediatric diseases. Led by Bruce D. Gelb, MD, at MCHDI we provide an intellectually rich and supportive environment for fostering collaborative scientific investigation and Mount Sinai’s bench to bedside philosophy, as well as training the next generation of scientific leaders in pediatric medicine.
Our physician-scientists and scientists work in a multidisciplinary manner with researchers and physicians in various departments and institutes across the Mount Sinai Health System. Together, we strive to develop robust paradigms for understanding the effects of genetics and the environment on the health of infants, children and adolescents, and personalizing medicine through genetics and genomics.
The Mount Sinai Health System carries a longstanding tradition of clinical and research innovation and accomplishments. Mount Sinai created one of the nation's first department of pediatrics, which now ranks in the top 20 in funding from the National Institutes of Health and other extramural granting agencies.
Research and Collaboration
At MCHDI, we build upon existing strengths that span several departments, institutes, and research programs in order to leverage resources and accelerate achievement.
Tapping into recent technologic advances, particularly in DNA sequencing, has brought clinicians and scientists to a breathtaking juncture, as it is now possible to sequence all of the protein-encoding portions of the human genome in a matter of days. These significant genomic strides help us to bring about remarkable translational research possibilities. Leveraging the Mount Sinai Health System’s leadership in genetics and genomics sciences, as well as environmental medicine, MCHDI has focused on the following areas of research emphasis to maximize our impact on new discoveries in asthma and allergy; cardiovascular disease; neurodevelopmental disorders; obesity and diabetes; and other childhood diseases.
Through various explorations of disease pathogenesis, we aim to augment the use of genetic information to improve the health of children. We are strongly committed to expanding the scientific infrastructure for genomic technology and developing new personalizing pediatric therapies, not only to maximize efficacy and reduce side effects, but also to improve diagnostic accuracy and outcome predictions.